| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/01/2008 | US7351554 Administering vaccine, native E7 protein, inactive fragment of the immunosuppressive and/or angiogenic native E7 protein;a DNA molecule encoding immunosuppressive and/or angiogenic native E7 protein inactivated by mutation; adjuvant of mucosal immunity |
| 04/01/2008 | US7351550 Exoenzyme toxin of Aeromonas salmonicida, and uses thereof |
| 04/01/2008 | US7351547 Kit for enhanced detection of multiple flaviviral infections |
| 04/01/2008 | US7351527 Isolated avirulent form of a carp virus, a double stranded DNA virus having a capsid with a icosahedron morphology and being of 90-110 nm in size and having 250,000 - 300,000 base pairs; causative agent of the disease affecting Cyprinus carpino; fish vaccines |
| 04/01/2008 | US7351435 Detoxification of ricin by complexing with antibodies |
| 04/01/2008 | US7351416 Administering to mammals, poultry; immunization; prevent sepsis, hemorrage, pneumonia, cholera; isolated Pasteurella; attenuation bacteria |
| 04/01/2008 | US7351415 Gene therapy; vaccines; storage stability; mixture containing viruses |
| 04/01/2008 | US7351413 Stabilized HBc chimer particles as immunogens for chronic hepatitis |
| 04/01/2008 | US7351412 Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated-virus (LAV) and proteins encoded by said LAV genomic RNA |
| 04/01/2008 | US7351409 Tumor antigens and CTL clones isolated by a novel procedure |
| 04/01/2008 | US7351408 Glycoconjugates and methods |
| 04/01/2008 | CA2341240C Autoantibody inhibitors |
| 04/01/2008 | CA2305623C Porcine circovirus, vaccines, and diagnostic reagents |
| 04/01/2008 | CA2217173C Isolation of a cdna clone encoding a subunit of the alternaria alternata major allergen alt a 1, and production of recombinant protein thereof |
| 03/27/2008 | WO2008036981A1 Methods for treating mica-related disorders |
| 03/27/2008 | WO2008036973A2 Modulating regulatory t cell activity via interleukin 35 |
| 03/27/2008 | WO2008036867A2 Methods for treatment of inflammatory disease and chlamydia infectious disease |
| 03/27/2008 | WO2008036838A2 Isolated complexes of covalently cross-linked endotoxin and modified md-2 |
| 03/27/2008 | WO2008036337A2 Predicted phosphorylation sites |
| 03/27/2008 | WO2008035350A1 Antigen specific multi epitope vaccines |
| 03/27/2008 | WO2008034857A1 Pestivirus mutant for use in a vaccine |
| 03/27/2008 | WO2008034608A1 The death receptor cd95 controls neurogenesis of adult neural stem cells in vivo and in vitro |
| 03/27/2008 | WO2008034388A1 Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof |
| 03/27/2008 | WO2008034181A1 ANTI-CANCER ANTIBODIES AGAINST LEWISy AND LEWISb ANTIGENS |
| 03/27/2008 | WO2008019144A3 Threapeutic methods for treating vascular eye disorders with dll4 antagonists |
| 03/27/2008 | WO2008008541A3 Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes |
| 03/27/2008 | WO2008006895A3 Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators |
| 03/27/2008 | WO2008005621A3 Compositions and methods for modulating immune responses |
| 03/27/2008 | WO2008003473A3 Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| 03/27/2008 | WO2007144772A3 Adjuvant-sparing multi-dose influenza vaccination regimen |
| 03/27/2008 | WO2007143004A3 Methods, compositions, and kits for treating shiga toxin associated conditions |
| 03/27/2008 | WO2007141274A3 Human binding molecules having killing activity against staphylococci and uses thereof |
| 03/27/2008 | WO2007134876A3 HIGH AFFINITY HUMAN AND HUMANIZED ANTI-α5β1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY |
| 03/27/2008 | WO2007100577A3 Development of a chlamydia sp. vaccine strain |
| 03/27/2008 | WO2007092939A3 Antigenic gm-csf peptides and antibodies to gm-csf |
| 03/27/2008 | WO2007076524A3 Human anti-il-23 antibodies, compositions, methods and uses |
| 03/27/2008 | WO2007067729A3 Microbial vaccine and vaccine vector |
| 03/27/2008 | WO2005122718A3 Kennel cough vaccine |
| 03/27/2008 | WO2005117971A3 Regulators of angiogenesis |
| 03/27/2008 | WO2003075845A3 Immunogenicity of glucan binding protein |
| 03/27/2008 | US20080076904 Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated |
| 03/27/2008 | US20080076709 Isolated polypeptide, encoded by nucleic acid sequence, a vector from Staphylococcus; use for activators or inhibitors in therapy, antigen for vaccination, antibodies; antibacterial agent treating Staphylococcus infections; biodrugs |
| 03/27/2008 | US20080076177 Plasmid comprising nucleotide sequences coding vaccine specific to newcastle disease virus hemagglutinin-neuraminidase (HN) for use in prevention and treatment of viral diseases in plants |
| 03/27/2008 | US20080076175 Generating transgenic lymphoid cell comprising sequences coding immunoglobulin epitope for use in tissue targeted therapies |
| 03/27/2008 | US20080076172 Vectors for tissue-specific replication |
| 03/27/2008 | US20080076161 Using expression vector comprising nucleotide sequences coding malaria antigen (LSA-NRC) and/or protein synthesis complex (MCP) to transform bacterial host and propagate preferential polypeptides |
| 03/27/2008 | US20080076136 Nucleotide sequences coding transport protein for use in identifying modulators for treatment of pain; flavor enhancement |
| 03/27/2008 | US20080075744 Pharmaceutical composition for cancer treatment containing cells that express a membrane cytokine |
| 03/27/2008 | US20080075743 antigenic material from one or more inactivated dermatophyte strains; stable immunogenic properties, easy preparation, high content of microconidia and lack of side reactions in animals; treating skin disorders |
| 03/27/2008 | US20080075742 synergistic biomedical activity as immunostimulants; biodrugs for prevention and/or treatment of cancer, treatment of allergic conditions, malignancies, chronic infections, autoimmune phenomena and age-related imbalances; adverse side effects of irradiation |
| 03/27/2008 | US20080075741 Recombinant P. falciparum merozoite protein-1 42 vaccine |
| 03/27/2008 | US20080075740 Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
| 03/27/2008 | US20080075739 Attenuated Salmonella SP12 Mutants as Antigen Carriers |
| 03/27/2008 | US20080075738 synthetic polypeptide biodrugs for treating viral disease; envelope protein, antigens, consisting of amino acid sequances from virus, more potent, protecting from T helper and B cell immunity |
| 03/27/2008 | US20080075737 inducing an immune response to an HIV antigen; genetic engineered polypeptide; inserted into cell; improves or restores the blood clotting time, blood disorders; gene therapy |
| 03/27/2008 | US20080075736 Materials and methods for respiratory disease control in canines |
| 03/27/2008 | US20080075735 Demethylated and/or oxidized membrane DNA |
| 03/27/2008 | US20080075734 Genetic Immunization |
| 03/27/2008 | US20080075733 receptor for advanced glycosylation end products polypeptide directly linked to a polypeptide comprising a CH2 domain of an immunoglobulin; biodrug for treating amyloidosis, Alzheimer's disease, cancer, autoimmune disease, inflammatory bowel disease, rheumatoid arthritis, psoriasis, multiple sclerosis |
| 03/27/2008 | US20080075732 Preparation of Antigen-Presenting Human Gamma-Delta T Cells and Use in Immunotherapy |
| 03/27/2008 | US20080075731 nanoparticle comprising a core made of a metal or polyoxyethylene glycol coatings, binding to core with lipoprotein binding agent, 7-alpha hydroxylase or antibody, and nicotinamide adenine dinucleotide; drug delivery particles; using a magnet to administer nanoparticles to target anatomical site |
| 03/27/2008 | US20080075730 Methods and compositions for treating biofilms |
| 03/27/2008 | US20080075729 ras-mediated; administering immunosuppressive for immune constituents that may interfere with the systemic delivery of the reovirus; antiproliferative; in the neoplastic cells phosphorylation of PKR is prevented by inactivation or deletion of PKR; antitumor agents |
| 03/27/2008 | US20080075728 Combination Therapies Of Hmgb And Complement Inhibitors Against Inflammation |
| 03/27/2008 | US20080075727 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| 03/27/2008 | US20080075726 Anti-IL-6 monoclonal antibodies and uses thereof |
| 03/27/2008 | US20080075725 Novel Immunointeractive Molecules and uses Thereof |
| 03/27/2008 | US20080075724 Nucleotide sequeces coding protein for use in the detection, diagnosis and treatment cell proliferative, autoimmune diseases, inflammation and infection; biodrugs as antiinflammatory agents, antiproliferative agents |
| 03/27/2008 | US20080075723 Endotheliase 2 ligands |
| 03/27/2008 | US20080075722 detecting the presence of a protein marker in patient sample, using a reagent which specifically binds with protein; comparing the copy number of a minimal common region; anticarcinogenic biodrugs |
| 03/27/2008 | US20080075721 Method of treating fibrosis |
| 03/27/2008 | US20080075720 fusion proteins comprising antibody variable domains that binds to factor B and a targeting moiety comprising a complement receptor or fragment, used to reduce or prevent airway hyperresponsiveness and inflammation, for treating ischemia-reperfusion injuries, rhinitis and respiratory system disorders |
| 03/27/2008 | US20080075719 Method for Augmenting B Cell Depletion |
| 03/27/2008 | US20080075718 biodegradable oligomers or polymers used for the controlled, localized and sustained delivery of drugs |
| 03/27/2008 | US20080075717 Antigen Imitating Extracellular Areas of Membrane Proteins of Type III Produced from Intracellular Pathogenic Micro-Organisms, Derived Conformational Antibodies and the Use Thereof |
| 03/27/2008 | US20080075716 purified and/or genetic engineered antibodies or fragments comprises variable heavy or light chain peptides capable of binding oxidized fragments of alipoproteins, used as vaccines against cardiovascular disorders |
| 03/27/2008 | US20080075715 modified polypeptides, whereby the modification results in a reduced number of potential lymphocyte epitopes that provides a reduced propensity for the polypeptide to elicit an immune response upon administration to a human, but retain the ability to bind to CD52 antigens |
| 03/27/2008 | US20080075714 Use of WNT inhibitors to augment therapeutic index of chemotherapy |
| 03/27/2008 | US20080075713 isomerase enzymes and ATP-binding cassette (ABC) transport proteins, used for controlling metabolism of triglycerides; diagnosis, prevention and treatment of metabolic disorders |
| 03/27/2008 | US20080075712 replacement for ligand of a heteromolecule-comprising a dimer, cytokine or interferon receptors; antibodies recognizing both an enzyme and a substrate, such as proteolytic enzymes and blood coagulation/fibrinolysis associated factors; prevention of bleeding and/or blood disorders |
| 03/27/2008 | US20080075708 compounds having an anchoring domain that anchors the compound to the surface of target cell, and a therapeutic domain that can act extracellularly to prevent infection of the target cell by a pathogen, such as viruses; neuraminidase |
| 03/27/2008 | US20080075705 induction of endogenous heat shock proteins in tumor cells, bysimple heat treatment as a method for augmenting antitumor vaccine potency |
| 03/27/2008 | US20080075696 Treatment Of Hepatitis C In The Asian Population With Interferon-Beta |
| 03/27/2008 | US20080075694 kits containing genetic engineered modified vaccinia virus ankara (MVA), which carries a nucleotide sequence that codes for a fusion protein, used for enhancing T cell responses in mammals |
| 03/27/2008 | US20080075693 Methods for treating viral infection using il-28 and il-29 cysteine mutants |
| 03/27/2008 | US20080075664 Control Of Diabetes And Obesity |
| 03/27/2008 | US20080075659 Determining the percentage of monoclonal, chimerized, murine or humanized antibody greater than 90 percent using excess amount of CD66 antigen, and the percentage of immunoreactive antibody that binds specifically to CD66 |
| 03/27/2008 | DE102007024383A1 Ddeodorant or antiperspirant composition comprises an antibody that is directed against a defined microorganism and is isolated from egg yolk |
| 03/27/2008 | DE102007024381A1 Topical composition for treating acne, pimples, bad skin or seborrhea comprises an antibody that is directed against a defined microorganism and is isolated from egg yolk |
| 03/27/2008 | DE102006042012A1 Verfahren zur Unterstützung von Immuntherapien Practices in support of immunotherapies |
| 03/27/2008 | CA2678994A1 Probiotics to reduce development of allergy in infants born by caesarean section |
| 03/27/2008 | CA2665816A1 Antigen specific multi epitope vaccines |
| 03/27/2008 | CA2665090A1 Methods for treating mica-related disorders |
| 03/27/2008 | CA2663994A1 Anti-cancer antibodies against lewisb and lewis antigens |
| 03/27/2008 | CA2663142A1 Pestivirus mutant for use in a vaccine |
| 03/27/2008 | CA2662613A1 Compositions and methods relating to glucagon receptor antibodies |
| 03/27/2008 | CA2660795A1 Optimized antibodies that target hm1.24 |
| 03/27/2008 | CA2659592A1 Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins |
| 03/27/2008 | CA2649387A1 Novel gene disruptions, compositions and methods relating thereto |
| 03/26/2008 | EP1903068A1 Biodegradable poly(beta-amino esters) and uses thereof |